A recent study indicates that individuals who come off new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who halt conventional diet and exercise regimens.
Research printed in a major health publication points out that while obese people often shed substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such drugs must be cognizant of the potential of rapid weight regain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain suggests a reversion to original mass within about one and a half years.
Weighing Approaches
The research, which reviewed dozens of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
The team note that individuals who lose weight through lifestyle changes alone usually have a less rapid creep back—perhaps 100 grams monthly—once they finish.
Explaining the Quick Regain
Nutrition scientists suggest the mode of action of the jabs accounts for the accelerated rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone concentrations several times higher than normal may cause the system to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating a significant risk."
An Ongoing Issue?
The NHS advise the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts argue that, due to the likelihood of relapse, the therapy might need to be life-long.
This perspective is echoed by pharmaceutical companies, who note that the results "emphasize the persistent nature of obesity," akin to managing diseases like diabetes.
User Testimonies
Users who have discontinued the medication report a intense resurgence of cravings.
"It was like something flipping and you become extremely hungry," described one woman.
This difficulty is compounded if individuals have not established permanent dietary or behavioural changes during therapy.
Growing Use
Survey data suggest that a significant number of people in the UK have used these injections in the past year, with interest remaining high.
- Adoption is greater among females than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while the jabs are effective agents for weight loss, they are not a magic cure and maintained weight loss hinges on integrated behavioural support.
